Adjuvant chemotherapy in colon carcinoma stages II and III

Short Review

Summary

Adjuvant chemotherapy significantly improves disease-free survival and overall survival in colon cancer. Ongoing clinical trials are evaluating the addition of targeted therapies to standard regimen and the influence of gene expression signature as prognostic and predictive markers for the use of adjuvant chemotherapy. This review will summarize adjuvant therapeutic approaches in stages III and II colon cancer as well as therapeutic options in elderly patients and future developments in the adjuvant setting of colon cancer.

Keywords

Colorectal cancer Adjuvant treatment Targeted therapy Elderly cancer patients 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mathers C, Boschi-Pinto C. Global burden of cancer in the year 2000: version 1 estimates. World Health Organization, Geneva, 2003Google Scholar
  2. O'Connell, Maggard MA, Ko CY, et al. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Nat Cancer Inst, 961420–961425, 2004Google Scholar
  3. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisol and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med, 322: 352–358, 1990PubMedCrossRefGoogle Scholar
  4. Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of flurouracil plus levamisole as adjuvant therapy for stage II/Dukes'B2 colon cancer. J Clin Oncol, 13: 2936–2943, 1995PubMedGoogle Scholar
  5. Porschen R, Bermann A, Löffler T, et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol, 19: 1787–1794, 2001PubMedGoogle Scholar
  6. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol, 17: 3553–3559, 1999PubMedGoogle Scholar
  7. O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16: 295–300, 1998PubMedGoogle Scholar
  8. Haller D, Catalano P, Macdonald J, et al. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancers: Five-year final report of INT-0089. Proc Am Soc Clin Oncol, 17: 982, 1998Google Scholar
  9. Köhne CH, Wils J, Lorenz M, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluoruracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol, 21: 3721–3728, 2003PubMedCrossRefGoogle Scholar
  10. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med, 352: 2696–2704, 2005PubMedCrossRefGoogle Scholar
  11. Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and Tegafur plus leucovorin compared with intravenous flourouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol, 24: 2059–2064, 2006PubMedCrossRefGoogle Scholar
  12. Popov I, Carrato A, Sobrero A, et al. Ralitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in adjuvant Colon Cancer 01 (PETACC-1). Eur J Cancer, 44: 2204–2211, 2008PubMedCrossRefGoogle Scholar
  13. André T, Boni C, Mounedji-Boudiaf L, et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the adjuvant treatment of colon cancer (MOSAIC). N Engl J Med, 350: 2343–2351, 2004PubMedCrossRefGoogle Scholar
  14. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol, 25: 2198–2204, 2007PubMedCrossRefGoogle Scholar
  15. Haller DG, Tabernero J, Maroun J, et al. First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin versus bolus 5-FU/LV for stage III colon cancer. Eur J Cancer Suppl, 7: 4, 2009CrossRefGoogle Scholar
  16. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). Proc Am Soc Clin Oncol, 23: 246 (Abstract 3500), 2004Google Scholar
  17. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol, 27: 3117–3125, 2009PubMedCrossRefGoogle Scholar
  18. Ychou M, Raoul JL, Douillard JY, et al. A phase III randomised trial of LV5FU2 + Irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol, 20: 674–680, 2009PubMedCrossRefGoogle Scholar
  19. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol, 22: 1797–1806, 2004PubMedCrossRefGoogle Scholar
  20. Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet, 370: 2020–2029, 2007PubMedCrossRefGoogle Scholar
  21. Sargent DJ, Patiyil S, Yothers G, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT group. J Clin Oncol, 25: 4569–4574, 2007PubMedCrossRefGoogle Scholar
  22. Benson AB, Schrag D, Somerfiled MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol, 22: 3408–3419, 2004PubMedCrossRefGoogle Scholar
  23. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med, 345: 1091–1097, 2001PubMedCrossRefGoogle Scholar
  24. McCleary J, Meyerhardt J, Green E, et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients with stage II/III colon cancer: findings from the ACCENT Database. J Clin Oncol, 27: 15 (Abstract 4010), 2009CrossRefGoogle Scholar
  25. Kabbinavar F, Hurwitz H, Fehrenbacher L, et al. Phase II randomized trial comparing bevacizumab plus fluorouracil/leucovorin with FU/LV in patients with metastatic colorectal cancer. J Clin Oncol, 21: 60–65, 2003PubMedCrossRefGoogle Scholar
  26. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, flurouracil and leucovorin for metastatic colorectal cancer. N Engl J Med, 350: 2335–2342, 2004PubMedCrossRefGoogle Scholar
  27. Saltz L, Diaz-Rubio E, Scheithauer W, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol, 26: 2013–2019, 2008PubMedCrossRefGoogle Scholar
  28. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med, 360: 1408–1417, 2009PubMedCrossRefGoogle Scholar
  29. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Overall survival of patients with KRAS wild-type tumors treated with FOLFOX4 + Cetuximab as 1st-line treatment for metastatic colorectal cancer: The Opus study. ECCO-ESMO, Abstract No 6.079, 2009Google Scholar
  30. Douillard JY, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol, 28: 4697–4705, 2010PubMedCrossRefGoogle Scholar
  31. Peeters M, et al. Randozmized phase III study of Panitumumab with fluorouracil, leucovorin and irinotectan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol, 28: 4706: 4713, 2010PubMedCrossRefGoogle Scholar
  32. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP Protocol C-08. J Clin Oncol, 29: 11–16, 2011PubMedCrossRefGoogle Scholar
  33. De Gramont A, Van Cutsem E, Tabernero J, et al. AVANT: Results form a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX-4 versus FOLFOX-4 alone as adjuvant treatment for colon cancer. ASCO GI 2011, Abstract 362Google Scholar
  34. Alberts SR, Sargent DJ, Smyrk TC, et al. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: results from NCCTG intergroup phase III trial N0147. J Clin Oncol, 28: 262 (Abstract CRA3507), 2010CrossRefGoogle Scholar
  35. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol, 28: 3219–3226, 2010PubMedCrossRefGoogle Scholar
  36. Kim ST, Lee J, Park SH, et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol, 66: 659–667, 2010PubMedCrossRefGoogle Scholar
  37. Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol, 27: 1814–1821, 2009PubMedCrossRefGoogle Scholar
  38. Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol, 29: 17–24, 2011PubMedCrossRefGoogle Scholar
  39. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol, 28: 466–474, 2010PubMedCrossRefGoogle Scholar
  40. Meyerhardt JA, Giovannucci EL, Holmes MD, et al. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol, 24: 3527–3534, 2006PubMedCrossRefGoogle Scholar
  41. Meyerhardt JA, Heseltine D, Niedwiecki D, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol, 24: 3535–3541, 2006PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Department of Internal Medicine IVKlinikum Wels-GrieskirchenWelsAustria

Personalised recommendations